Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
OBJECTIVES: The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.
METHODS: Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months.
RESULTS: CMV IgG and IgM positivity was seen in 51% and 6% of the patients, respectively. In multivariate analysis CMV IgG and CMV IgM serology show an age-depending effect for PFS. We identified positive CMV IgG/positive CMV IgM serology as an age-depending beneficial factor on PFS.
DISCUSSION: Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Hematology (Amsterdam, Netherlands) - 29(2024), 1 vom: 31. Feb., Seite 2320006 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salwender, Hans [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.02.2024 Date Revised 27.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/16078454.2024.2320006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368971627 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368971627 | ||
| 003 | DE-627 | ||
| 005 | 20240229165051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/16078454.2024.2320006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368971627 | ||
| 035 | |a (NLM)38407192 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salwender, Hans |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2024 | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown | ||
| 520 | |a METHODS: Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months | ||
| 520 | |a RESULTS: CMV IgG and IgM positivity was seen in 51% and 6% of the patients, respectively. In multivariate analysis CMV IgG and CMV IgM serology show an age-depending effect for PFS. We identified positive CMV IgG/positive CMV IgM serology as an age-depending beneficial factor on PFS | ||
| 520 | |a DISCUSSION: Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CMV | |
| 650 | 4 | |a CMV IgM | |
| 650 | 4 | |a CMV-Infection | |
| 650 | 4 | |a GMMG-MM5 Phase III Trial | |
| 650 | 4 | |a age-depending effect | |
| 650 | 4 | |a autologous stem cell transplantation | |
| 650 | 4 | |a maintenance therapy | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 7 | |a cytomegalovirus-specific hyperimmune globulin |2 NLM | |
| 650 | 7 | |a 129L90A25N |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Weinhold, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Benner, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Miah, Kaya |e verfasserin |4 aut | |
| 700 | 1 | |a Merz, Maximilian |e verfasserin |4 aut | |
| 700 | 1 | |a Haenel, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Jehn, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Mai, Elias |e verfasserin |4 aut | |
| 700 | 1 | |a Menis, Ekaterina |e verfasserin |4 aut | |
| 700 | 1 | |a Blau, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Scheid, Christof |e verfasserin |4 aut | |
| 700 | 1 | |a Hose, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Seckinger, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Luntz, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Besemer, Britta |e verfasserin |4 aut | |
| 700 | 1 | |a Munder, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Brossart, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Glass, Bertram |e verfasserin |4 aut | |
| 700 | 1 | |a Lindemann, Hans-Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Weisel, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Hanoun, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Schnitzler, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Klemm, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |e verfasserin |4 aut | |
| 700 | 1 | |a Raab, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Elmaagacli, Ahmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology (Amsterdam, Netherlands) |d 1996 |g 29(2024), 1 vom: 31. Feb., Seite 2320006 |w (DE-627)NLM096477237 |x 1607-8454 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:1 |g day:31 |g month:02 |g pages:2320006 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/16078454.2024.2320006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 1 |b 31 |c 02 |h 2320006 | ||